

IMPLEMENTATION GUIDANCE FOR NICE TA 694: BEMPEDOIC ACID WITH EZETIMIBE FOR TREATING PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDAEMIA


NICE (TA 694) recommends Bempedoic acid with ezetimibe as an option for treating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia as an adjunct to diet in adults ONLY when:

- statins are contraindicated or not tolerated
- ezetimibe alone does not control low-density lipoprotein cholesterol well enough

IMPORTANT: NICE RECOMMENDS BEMPEDOIC ACID (NILEMDO®) MAY BE USED ONLY IN COMBINATION WITH EZETIMIBE

See below algorithm to support clinicians with implementation of the guidance

TREATMENT ALGORITHM FOR PRIMARY HYPERCHOLESTEROLEMIA/MIXED DYSLIPIDAEMIA



STATIN INTOLERANCE
Multiple trials of various statins may be required to establish true intolerance
Intolerance to statin therapy is defined as the presence of clinically significant adverse effects that represent an unacceptable risk to the patient or that may reduce compliance with therapy.

Monitoring requirements
LFTs, U&Es and urate at baseline, 2-3 months and 6-12 months as per clinical need.

Prescribing
Bempedoic acid may be initiated by both primary and secondary care clinicians. If necessary, primary care clinicians may seek specialist advice prior to initiation via the usual pathway, including for patients with associated hypertriglyceridemia.

Bempedoic acid can be used as separate tablets (Nilemdo®) with ezetimibe or as the fixed-dose combination (Nustendi®) Both Nilemdo® and Nustendi® have similar pricing.
Reference: <https://www.nice.org.uk/guidance/ta694/chapter/1-Recommendations>